BRPI0520654B8 - composições de sulfoalquil éter ciclodextrina e processo para preparação das mesmas - Google Patents

composições de sulfoalquil éter ciclodextrina e processo para preparação das mesmas

Info

Publication number
BRPI0520654B8
BRPI0520654B8 BRPI0520654A BRPI0520654A BRPI0520654B8 BR PI0520654 B8 BRPI0520654 B8 BR PI0520654B8 BR PI0520654 A BRPI0520654 A BR PI0520654A BR PI0520654 A BRPI0520654 A BR PI0520654A BR PI0520654 B8 BRPI0520654 B8 BR PI0520654B8
Authority
BR
Brazil
Prior art keywords
sae
preparing
composition
same
sulfoalkyl ether
Prior art date
Application number
BRPI0520654A
Other languages
English (en)
Inventor
B Hecker Douglas
L Mosher Gerold
D Pipkin James
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37968086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0520654(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Publication of BRPI0520654A2 publication Critical patent/BRPI0520654A2/pt
Publication of BRPI0520654B1 publication Critical patent/BRPI0520654B1/pt
Publication of BRPI0520654B8 publication Critical patent/BRPI0520654B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D1/00—Evaporating
    • B01D1/16—Evaporating by spraying
    • B01D1/18—Evaporating by spraying to obtain dry solids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

composições de sulfoalquil éter ciclodextrina e métodos de preparação das mesmas uma composição particulada de sae-cd é provida. a composição de sae-cd tem uma combinação vantajosa de propriedades físicas não encontradas em formas sólidas conhecidas de sae-cd. em particular, a composição de sae-cd possui um perfil de propriedades fisicoquímicas e morfológicas tal que pode ser talhada para usos particulares. a composição de sae-cd da invenção tem desempenho de fluxo e dissolução melhorado quando comparada com as composições de sae-cd conhecidas.
BRPI0520654A 2005-10-26 2005-10-26 composições de sulfoalquil éter ciclodextrina e processo para preparação das mesmas BRPI0520654B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/038933 WO2007050075A1 (en) 2005-10-26 2005-10-26 Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof

Publications (3)

Publication Number Publication Date
BRPI0520654A2 BRPI0520654A2 (pt) 2009-05-19
BRPI0520654B1 BRPI0520654B1 (pt) 2020-08-11
BRPI0520654B8 true BRPI0520654B8 (pt) 2021-05-25

Family

ID=37968086

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520654A BRPI0520654B8 (pt) 2005-10-26 2005-10-26 composições de sulfoalquil éter ciclodextrina e processo para preparação das mesmas

Country Status (21)

Country Link
US (1) US8049003B2 (pt)
EP (5) EP2581078B1 (pt)
JP (1) JP5465432B2 (pt)
KR (1) KR101152886B1 (pt)
CN (1) CN101365459B (pt)
AT (1) ATE504305T1 (pt)
AU (1) AU2005337613B2 (pt)
BR (1) BRPI0520654B8 (pt)
CA (2) CA2928065C (pt)
CY (3) CY1116080T1 (pt)
DE (1) DE602005027415D1 (pt)
DK (5) DK1945228T4 (pt)
ES (5) ES2542893T3 (pt)
HU (2) HUE035181T2 (pt)
IL (3) IL191081A (pt)
LT (1) LT2952197T (pt)
MX (2) MX383536B (pt)
PL (4) PL2335707T3 (pt)
PT (5) PT1945228E (pt)
SI (2) SI2952197T1 (pt)
WO (1) WO2007050075A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061088A1 (en) * 2003-12-22 2005-07-07 Finlay Warren H Powder formation by atmospheric spray-freeze drying
PL2708225T3 (pl) * 2004-04-23 2019-07-31 Cydex Pharmaceuticals, Inc. Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
WO2009018069A2 (en) * 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
US8501740B2 (en) * 2007-10-09 2013-08-06 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
KR101868117B1 (ko) 2010-08-05 2018-06-18 시가 테크놀로지스, 인크. Ｓｔ­246 액체 제형 및 방법
HUE037660T2 (hu) 2011-01-26 2018-09-28 Allergan Inc Androgén készítmény szembetegség kezelésére
US8992987B2 (en) 2011-04-06 2015-03-31 Dow Global Technologies Llc Polysaccharide derivatives and dosage forms
EP4083075A1 (en) 2012-02-15 2022-11-02 CyDex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
HK1211311A1 (en) * 2012-02-28 2016-05-20 锡德克斯药物公司 Alkylated cyclodextrin compositions and processes for preparing and using the same
HK1213585A1 (zh) 2012-10-22 2016-07-08 Cydex Pharmaceuticals, Inc. 烷基化环糊精组合物及其制备和使用方法
MA38121A1 (fr) * 2012-11-30 2016-10-31 Glaxosmithkline Llc Nouvelle composition pharmaceutique
PT3183295T (pt) 2014-08-22 2023-11-03 Cydex Pharmaceuticals Inc Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas
EP4620534A3 (en) 2015-03-19 2025-12-24 CyDex Pharmaceuticals, Inc. Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
EP3097962B1 (de) * 2015-05-29 2020-05-13 Symrise AG Vorrichtung zur herstellung von sprühgetrockneten agglomeraten
EP3525792A4 (en) * 2016-10-11 2020-04-22 Aucta Pharmaceuticals POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGIN
US20180318249A1 (en) 2017-05-03 2018-11-08 Cydex Pharmaceuticals, Inc. Composition containing cyclodextrin and busulfan
EP3906019B1 (en) 2019-01-04 2025-11-26 SQ Innovation AG Pharmaceutical compositions of furosemide
EP3906020B1 (en) 2019-01-04 2025-12-31 SQ Innovation AG Pharmaceutical compositions of torsemide and their uses
AU2020312165A1 (en) * 2019-07-09 2022-01-20 Basf Se Tableting of specific polymer stabilizers
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
IL321589A (en) 2019-08-01 2025-08-01 Incarda Therapeutics Inc Antiarrhythmic formulation comprising a salt of flecainide
US20230227506A1 (en) 2020-06-18 2023-07-20 The University Of Bristol Fatty Acid Complexes Of Coronavirus Spike Protein And Their Use
WO2022029334A1 (en) 2020-08-07 2022-02-10 Gbiotech S.À.R.L. Combination therapies for treating coronavirus infection
JP2024516464A (ja) 2021-05-06 2024-04-15 スペファーム アーゲー 医薬製剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
EP0163836B1 (de) 1984-04-07 1988-10-12 Bayer Ag Verfahren und Vorrichtung zur Herstellung von Granulaten
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
DK0392608T3 (da) 1989-04-12 1995-11-20 Procter & Gamble Faste konsumentproduktsammensætninger, der indeholder cyclodextrinkomplekser af lille partikelstørrelse
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1991018022A1 (en) 1990-05-21 1991-11-28 Toppan Printing Co., Ltd. Cyclodextrin derivative
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
IL111184A (en) 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
FR2735136B1 (fr) 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
US5935941A (en) 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
DK0889056T3 (da) 1997-07-01 2006-07-17 Pfizer Prod Inc Process for making a cyclodextrin
JP2003522207A (ja) 1998-02-23 2003-07-22 サイクロプス・イーエイチエフ 高エネルギーシクロデキストリン複合体
MA25590A1 (fr) 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
AUPR272901A0 (en) * 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
FR2821844B1 (fr) 2001-03-08 2003-05-23 Roquette Freres Procede de preparation d'une beta-cyclodextrine directement compressible, et beta-cyclodextrine directement compressible ainsi obtenue
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030028014A1 (en) 2001-04-26 2003-02-06 Chris Sikorski Agglomerated modified cyclodextrin and process for making same
DE10240698A1 (de) * 2002-09-04 2004-03-18 Symrise Gmbh & Co. Kg Cyclodextrinpartikel
WO2005042584A2 (en) 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
BRPI0418276B8 (pt) * 2003-12-31 2021-05-25 Cydex Pharmaceuticals Inc formulação líquida inalável compreeendendo budesonida
PL2708225T3 (pl) 2004-04-23 2019-07-31 Cydex Pharmaceuticals, Inc. Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny
WO2006011051A1 (en) 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060194762A1 (en) 2004-12-23 2006-08-31 Olaf Reer Composition comprising an epothilone and methods for producing a composition comprising an epothilone
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions

Also Published As

Publication number Publication date
EP1945228A4 (en) 2010-04-07
EP2581078B1 (en) 2014-12-10
EP1945228B2 (en) 2014-11-05
PL2952197T3 (pl) 2017-09-29
PT1945228E (pt) 2011-07-13
JP5465432B2 (ja) 2014-04-09
EP2952197A1 (en) 2015-12-09
HK1184070A1 (en) 2014-01-17
CY1119471T1 (el) 2018-03-07
PT2335707E (pt) 2015-09-10
HK1184383A1 (en) 2014-01-24
IL269619B (en) 2020-07-30
ES2542893T3 (es) 2015-08-12
EP2581078A1 (en) 2013-04-17
IL191081A0 (en) 2009-08-03
EP2583668B1 (en) 2014-10-08
HUE025315T2 (en) 2016-02-29
CA2928065A1 (en) 2007-05-03
EP1945228B1 (en) 2011-04-06
KR20080063526A (ko) 2008-07-04
PL2583668T3 (pl) 2015-05-29
DK2952197T3 (en) 2017-08-07
EP2952197B1 (en) 2017-04-26
DK1945228T3 (da) 2011-07-25
MX348982B (es) 2017-07-06
PT2581078E (pt) 2015-03-10
CY1116080T1 (el) 2017-02-08
SI2952197T1 (sl) 2017-09-29
DK2583668T3 (en) 2015-01-19
US8049003B2 (en) 2011-11-01
IL191081A (en) 2016-03-31
BRPI0520654A2 (pt) 2009-05-19
PL2581078T3 (pl) 2015-07-31
KR101152886B1 (ko) 2012-07-09
EP2335707A1 (en) 2011-06-22
CN101365459A (zh) 2009-02-11
CA2632211A1 (en) 2007-05-03
LT2952197T (lt) 2017-08-25
ES2532374T3 (es) 2015-03-26
CN101365459B (zh) 2011-11-30
EP2583668A1 (en) 2013-04-24
IL244130B (en) 2020-06-30
CA2632211C (en) 2016-07-05
CA2928065C (en) 2019-10-15
DK2581078T3 (en) 2015-03-02
ES2364491T3 (es) 2011-09-05
HUE035181T2 (hu) 2018-05-02
EP1945228A1 (en) 2008-07-23
AU2005337613B2 (en) 2011-04-28
PT2952197T (pt) 2017-07-28
IL269619A (en) 2019-11-28
DE602005027415D1 (de) 2011-05-19
ES2526903T3 (es) 2015-01-16
ES2634670T3 (es) 2017-09-28
AU2005337613A1 (en) 2007-05-03
EP2335707B1 (en) 2015-05-06
JP2009513773A (ja) 2009-04-02
DK2335707T3 (en) 2015-08-10
SI2335707T1 (sl) 2015-09-30
BRPI0520654B1 (pt) 2020-08-11
HK1158978A1 (en) 2012-07-27
CY1116517T1 (el) 2017-03-15
EP1945228B9 (en) 2015-03-11
WO2007050075A1 (en) 2007-05-03
ES2364491T5 (es) 2015-02-19
MX383536B (es) 2025-03-14
PL2335707T3 (pl) 2015-10-30
PT2583668E (pt) 2015-01-05
HK1218509A1 (en) 2017-02-24
DK1945228T4 (da) 2015-01-12
ATE504305T1 (de) 2011-04-15
US20090011037A1 (en) 2009-01-08
IL244130A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
BRPI0520654A2 (pt) composições de sulfoalquil éter ciclodextrina e métodos de preparação das mesmas
MX2009011181A (es) Uso nuevo del hidroxitirosol.
BR112015007393A2 (pt) método para conversão de biomassa lignocelulósica, sistema de conversão de biomassa lignocelulósica, e, composição
BRPI0601896A (pt) composições que contêm microgéis e agentes espessantes
BRPI0710485A8 (pt) composições e métodos úteis para tratamento de doenças respiratórias
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
BR112013013900A2 (pt) composição, uso de um éter polissacarídeo linear hidroxílico de alquila inferior hidrofobicamente modificado não iônico solúvel em água, método para o tratamento de uma planta e método para melhorar a deposição, sobre uma planta, de uma composição aquosa
EA200701656A1 (ru) Противообледенительная и/или антиобледенительная композиция и способ уменьшения температуры застывания сложных эфиров растительных масел (варианты)
BR112013028832A2 (pt) composição alimentícia, uso de éter de celulose e método para melhorar uma ou mais das propriedades de uma composição alimentícia
BRPI0417672A (pt) processos para produzir composições de vìrus estáveis em armazenamento, composições de vìrus e imunogênicas
CL2008002758A1 (es) Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento.
BR112014032254A2 (pt) processo para a preparação de uma composição, aparelho, e, uso de um aparelho
BRPI0519605A2 (pt) composiÇÕes de cuidado pessoal
DE602006009144D1 (de) Zusammensetzungen für die verbesserung der darmgesundheit und der tierischen leistung enthaltend beta-glucans and alfa-fucans
AR074747A1 (es) Mejoras relacionadas con composiciones para el tratamiento de telas
BR112015015202B8 (pt) Composição
ECSP089024A (es) Camsilato de (s)-(-)-amlodipino o hidrato del mismo y composición farmacéutica que comprende el mismo
MX2021006926A (es) Composiciones de eter sulfoalquilico-ciclodextrina y metodos de preparacion de las mismas.
TW200511987A (en) Topical composition
MX2019014969A (es) Composicion acondicionadora del cabello para enjuague mejorado.
UA29280U (en) Nanometal aquachelate
AR069744A1 (es) Composiciones de limpieza naturales
TH156262A (th) องค์ประกอบซึ่งมีไฮดรอกซิเอธิลเซลลูโลส
BRPI0501241A (pt) composição cosmética, composição farmacêutica e processo para preparação das referidas composições

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22B Petition not considered [chapter 22.2 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 870210067740, DE 26/07/2021, EM VIRTUDE DO DISPOSTO NO ART. 219 , INCISO II DA LPI

B12F Other appeals [chapter 12.6 patent gazette]

Free format text: RECURSO: 870220058740 - 4/07/2022